Boston, MA 07/12/2013 (wallstreetpr) – Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)’s stock closed at $5.70. The opening of the stock was at $5.15 and it made an intraday high at $5.72. In trading session on Thursday, no shares were traded as against the average volume of 527,781.00 shares in the last 90 trading sessions.
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) is a biopharmaceutical Company that actively conducts research and development for products candidates of biotechnology in virology, oncology, gastroenterology and supportive care. The Company also conducts research for identifying multiplex phosphoinositide 3-kinase inhibitors to block signaling pathways in the aggressive cancers’ growth. The Company’s foremost commercial product in gastroenterology is RELISTOR subcutaneous injection. The chief product candidate of the Company is PSMA ADC which is a completely human monoclonal antibody-drug conjugate aimed against prostate specific membrane antigen.
As per the reports by TheFlyOnTheWall.com, Progenics Pharmaceuticals (NASDAQ: PGNX) got an upgraded rating of “buy” from the previous “hold” rating by Brean Capital’s equities researchers. The report was issued on Monday. Presently, the stock of the firm has been given a price target of $9.00.
The quarterly earnings results of Progenics Pharmaceuticals (NASDAQ: PGNX) was last published on Friday, May 10th. In the report, the company showed Earnings per Share (EPS) of $0.22 for the quarter. This figure missed the previously estimated amount of by $0.33. The consensus amount was set at $0.19. The revenue of the Company for the quarter stood at $2.23 million. The consensus estimate of the quarter’s revenue was $1.71 million. In the previous year, for the same quarter, $0.39 Earnings per Share were posted by the Company. It is predicted by the analysts that on an average, Progenics Pharmaceuticals (NASDAQ: PGNX) will post earnings per share of $-0.75 for the current fiscal year.
